Paris (France), April 14, 2023 – 5:35 p.m. CEST – Onxeo SA (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) mechanisms ) and pilot oncogenes, today announces a new date for the publication of its 2022 annual results.
The publication of the 2022 annual results has been postponed to April 21, 2023, after market close.
To receive all of ONXEO’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.